Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00951405 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00951405 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 23 participants.
The verdict
NCT00951405, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe, Japan and North America. The aim of this clinical trial is to investigate the safety and the efficacy of a prophylactic treatment option with long acting coagulation factor VII (LA-rFVIIa) for haemophilia patients with inhibitors.
Interventions
- DRUG activated recombinant human factor VII, long acting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-09-01 |
| Est. Completion | 2011-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00951405
The ClinicalTrials.gov registry entry for NCT00951405 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which activated recombinant human factor VII, long acting is the first listed.
NCT00951405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00951405 about?
NCT00951405 is a clinical study titled "Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors". This trial is conducted in Asia, Europe, Japan and North America. The aim of this clinical trial is to investigate the safety and the efficacy of a prophylactic treatment option with long acting coagulation factor VII (LA-rFVIIa) for haemophilia patients with inhibitors.
What is the current status of trial NCT00951405?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2009-09-01. Estimated completion is 2011-03-29.
What interventions are being tested in trial NCT00951405?
The interventions under investigation include: activated recombinant human factor VII, long acting (DRUG).
Who is sponsoring clinical trial NCT00951405?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.